Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia
2007; Elsevier BV; Volume: 19; Issue: 1 Linguagem: Inglês
10.1093/annonc/mdm451
ISSN1569-8041
AutoresLuana Fianchi, Livio Pagano, Fabiana Leoni, Sergio Storti, Maria Teresa Voso, Caterina Giovanna Valentini, Sergio Rutella, Alessandra Scardocci, Morena Caira, Giacomo Gianfaldoni, Giuseppe Leone,
Tópico(s)Neutropenia and Cancer Infections
ResumoBackgroundGemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients.Patients and methodsIn three Italian hematology departments from September 2003 to September 2006, 53 elderly patients [median age 69 years (range 65–77)] with untreated or primary refractory/relapsed AML were enrolled on the combination G-AraMy administered according to two consecutive schedules (G-AraMy1 and G-AraMy2), with intensified consolidation in the second. Twenty-three of 53 patients had a secondary acute myeloid leukemia (sAML).ResultsThe overall response rate was 57%. The most common adverse event was myelosuppression. Seven patients died in induction (13%). No differences for response rate and toxicity profile were observed between untreated and primary resistant/relapsed patients, de novo AML and sAML, and in the two treatment trials. Median disease-free survival and overall survival were 8 months (range 2–23+) and 9 months (range 2–24+).ConclusionsG-AraMy therapy may be considered an useful treatment approach for poor-risk elderly AML patients, with a complete remission rate comparable to literature data with reduced side-effects, also in a poor-prognosis population.
Referência(s)